- The UAE is considering building a third crude oil pipeline to bypass the Strait of Hormuz.
- The U.S. trade deficit narrowed slightly in September as goods exports rose to a four-month high.
- NASDAQ TRADE HALT <VCIG.O> VOLATILITY TRADING PAUSE AT 09:35 AM
- AMEX HALT <VRC.A> ADD INFO LST 12.252600
- NASDAQ TRADE HALT <CRIS.O> VOLATILITY TRADING PAUSE AT 09:34 AM
- FIS <FIS.N>: JP MORGAN CUTS TO NEUTRAL FROM OVERWEIGHT; CUTS TARGET PRICE TO $38 FROM $53
- Brazilian Real: Rate-cut pause but medium-term gains – Commerzbank
- Bitcoin, Silver, and Copper Flash Warning Signs of a Massive Market Sell-Off
- NASDAQ TRADE HALT <INIO.O> VOLATILITY TRADING PAUSE AT 09:33 AM
- NASDAQ TRADE HALT <SRTS.O> VOLATILITY TRADING PAUSE AT 09:31 AM
- BUZZ - Fintech company SS&C shares drop after announcing a $1.1 billion convertible bond issuance plan
- Oncolytics Biotech's Pelareorep Boosts HPV-Specific Immune Responses in Anal Cancer Study
- Tradewinds Universal Pursues Energy Expansion Through Talks With Power Technology License Holder
- NASDAQ TRADE HALT <BRKRP.O> VOLATILITY TRADING PAUSE AT 09:30 AM
- NASDAQ TRADE HALT <CRAM.O> VOLATILITY TRADING PAUSE AT 09:30 AM
- Gem Diamonds lifts 2026 outlook on big-stone windfall
- BRIEF-Toronto Stock Exchange rises at open
- Xerox Holdings Announces Dividend of R$ 0.0892715490 Per Unit
- Cosmos Health Expects Amazon UK Sales to Rise 72% to $3.9 Million Over Next 12 Months
- Amadeus Fire narrows FY 2026 operating EBITA outlook to EUR 17-20 million
- US Stock Market Movement | European bank stocks generally rise before the opening, Deutsche Bank (DB.US) up nearly 7%
- Clariant Publishes Q3 2026 Results Call Transcript
- Anteros Metals reports 1.10% copper over 4 meters at Havens Steady property
- Person associated with SBE-Varvit directors Alessandro Alberto and Federico Vescovini buys EUR 2,722.72 in ordinary shares
- Faron reports 85% response rate in frontline higher-risk MDS trial of bexmarilimab combination
- Marzetti Publishes Fiscal 2027 First-Quarter Earnings Call Transcript
- PROS Partners With IBS Software on Airline Offer and Order Management Platform
- Arkema Reports 77,065,468 Shares Outstanding as of Oct. 31, 2026
- BUZZ - US new cloud concept stocks fall after Democrats' sweeping victory
- Adobe integrates enterprise collaboration tools with AI platforms from Anthropic, Google, Microsoft, and OpenAI.
- Clarivate launches cash tender offers for up to $500 million in notes
- Tyler Technologies Plans to Attend Five Investor Conferences
- Gilead and Kite Present Blood Cancer Therapy Data at ASH Annual Meeting
- Gilead to Present 18-Month Anito-cel Trial Follow-Up Data in Multiple Myeloma at ASH 2026
- RedCloud CEO to Attend 15th Annual ROTH Technology Conference
- Cullinan Therapeutics Reports Anti-Leukemic Activity in Phase 1 CLN-049 Study
- Immix Biopharma to Present NXC-201 Trial Data From 45 Patients at ASH 2026
- Rigel Announces Phase 1b R289 Data Presentation in Lower-Risk MDS at ASH
- Autolus data show leukemia responses deepen beyond first month after obe-cel treatment
- Siemens Healthineers publishes update to financial calendar
- Actinium Pharmaceuticals highlights Iomab-ACT clinical results in CAR T-cell therapy at ASH 2026
- Terreno Realty Signs 82,000-Square-Foot Lease in Avenel, New Jersey
- Agilent Completes Acquisition of Proscia
- Stanley Black & Decker 3Q 2026 net earnings rise to $272.1 million
- Datadog's 4Q Outlook Fails To Top Expectations, Largest Customer Reins in Usage -- Market Talk
- CVS Health outlines plan to split into two independent publicly traded companies
- Boron One Signs Three-Year Boron Supply Agreement With Singapore-Based Distributor
- Kura Oncology to Present First Ziftomenib-FLT3 Inhibitor Combination Trial Data at ASH 2026
- Lyell Immunopharma Announces $80 Million Private Placement
- BioMarin to Present at Stifel, UBS and Jefferies Investor Conferences
- Agilent Completes Acquisition Of Proscia >A
- Castor Maritime Subsidiary Agrees to Buy 41% Stake in Marlow Navigation for USD 126 Million
- Syndax Hosts Investor Event to Discuss ASH Data
- Lyell Immunopharma's Ronde-Cel Achieves 77% Complete Response Rate in Pivotal Lymphoma Trial
- Karyopharm reports sustained benefit through 48 weeks in Phase 3 selinexor myelofibrosis trial
- CRISPR Therapeutics Presents Zugo-cel Lymphoma Data at ASH Annual Meeting
- Sierra Bancorp Publishes Hovde Investor Conference Presentation
- Ferrovial Raised to Buy From Neutral by Citigroup
- UWM Shares Rise After Q3 Adjusted Earnings Beat
- Volatus Aerospace, Calian Group, Instrumar to Collaborate on Arctic Uncrewed Aircraft Systems
- BofA Adjusts Price Target on Associated Banc-Corp to $32 From $34
- NewAmsterdam Pharma's Q3 Net Loss Narrows, Revenue Grows
- Sherritt International to 'Temporarily' Lay off 47% of its Canadian Workforce
- Peabody Energy Q3 Loss Narrows as Revenue Rises
- Sprott Q3 Earnings, Revenue Rise
- UniQure Q3 Loss Narrows, Revenue Increases
- Adient Fiscal Q4 Adjusted Earnings Flat, Revenue Rises
- BioCryst Pharmaceuticals' Q3 Net Income, Revenue Rise; Increases 2026 Revenue Guidance
- Phoenix Metals Appoints Carol Li as CFO
- Natural Resource Partners Q3 Net Income, Revenue Drop
- RBC Cuts Price Target on XPLR Infrastructure to $12 From $14, Keeps Outperform Rating
- Sector Update: Financial Stocks Edge Higher Pre-Bell Wednesday
- Sector Update: Healthcare Stocks Advance Premarket Wednesday
- Exchange-Traded Funds, Equity Futures Rise Pre-Bell Wednesday as Investors React to US Midterm Election Results
- RBC Raises Price Target on Waters to $525 From $475, Keeps Outperform Rating
- MGE Energy Q3 Earnings, Revenue Rise
- Navios Maritime Partners Q3 Adjusted Earnings, Revenue Increase
- Sector Update: Consumer Stocks Rise Pre-Bell Wednesday
- Zimmer Biomet Holdings Had Seen 2026 Adjusted EPS $8.47-$8.59 >ZBH
- Ralliant Sees 2026 Rev $2.34B-$2.36B >RAL
- Ralliant: Delivered Another Strong Qtr, Exceeding the High End of Our Expectations and Contributing to Raised full-Yr 2026 Guidance >RAL
- ESAB Updates 2026 Total Core Sales Growth to 13.1%-13.3% From 11%-14%>ESAB
- Zimmer Biomet Holdings Raises 2026 View To Adj EPS $8.50-Adj EPS $8.60 >ZBH
- CVS Health Raises 2026 Adjusted EPS Guidance to at Least $8.20 from Prior View $7.90-$8.10 >CVS
- CVS Health: 3Q Adjusted EPS Rose Primarily Due to Improved Adjusted Operating Income in Health Care Benefits Segment >CVS
- CVS Health 3Q Adj. Operating Income $1.64B >CVS
- CVS Health: 3Q Health Services Segment Rev Rose Primarily Driven by Pharmacy Drug Mix and Brand Inflation, Partially Offset by Continued Pharmacy Client Price Improvements >CVS
- CVS Health 3Q Same-Store Prescription Volume Rose 3.9% >CVS
- Kennametal Sees 2Q Sales $785M-$815M >KMT
- Westlake Chemical Ptrs 3Q Rev $314.5M >WLKP
- CVS Health 3Q Pharmacy & Consumer Wellness Segment Revenue Down 2% >CVS
- CVS Health Raises 2026 Cash Flow from Operations Guidance to at Least $15.5B from at Least $11.5B >CVS
- Westlake Chemical Ptrs 3Q EPS 46c >WLKP
- CVS Health Raises 2026 EPS Guidance to at Least $6.98 from Prior View $6.84-$7.04 >CVS
- CVS Health Health Care Benefits Segment's 3Q Medical Benefit Ratio 91.3% >CVS
- CVS Health 3Q Prescriptions Filled Rose 1.9% on 30-Day Equivalent Basis >CVS
- CVS Health 3Q Health Services Segment Revenue Up 9.5% >CVS
- CVS Health 3Q Healthcare Benefits Segment Revenue Up 2.4% >CVS
- CVS Health: 3Q Health Care Benefits Segment Rev Rose Primarily Driven by Increase in Govt Business, Partially Offset by Decline as Result of CO's Exit of Individual Exchange Business in 2026 >CVS
- CVS Health 3Q Pharmacy & Consumer Wellness Segment Revenue $35.5B >CVS
